Showing results (31-40 of 46) with videos related to

Sort By:
Pageof 5
Endocrinology|April 2, 2010
Identification of a novel role for endothelins within the oviductMyoungkun Jeoung, Sungeun Lee, Hee-Kyung Hawng, et al.
Anesthesiology|January 31, 2002
Involvement of renin-angiotensin system in pressure-flow relationship: role of angiotensin-converting enzyme gene polymorphismSigismond Lasocki, Marc Iglarz, Pierre-François Seince, et al.
Fundamental & Clinical Pharmacology|April 9, 2025
Dual ETA-ETB receptor antagonism improves metabolic syndrome-induced heart failure with preserved ejection fractionFrancesca Lockwood, Marianne Lachaux, Najah Harouki, et al.
The European Respiratory Journal|July 7, 2018
Macitentan reduces progression of TGF-β1-induced pulmonary fibrosis and pulmonary hypertensionPierre-Simon Bellaye, Toyoshi Yanagihara, Elise Granton, et al.
Experimental Lung Research|January 12, 2018
Granulomatous lung inflammation is nanoparticle type-dependentYves Pacheco, Marine Ponchon, Serge Lebecque, et al.
Oxidative Medicine and Cellular Longevity|January 29, 2019
The Endothelin Receptor Antagonist Macitentan Improves Isosorbide-5-Mononitrate (ISMN) and Isosorbide Dinitrate (ISDN) Induced Endothelial Dysfunction, Oxidative Stress, and Vascular InflammationSebastian Steven, Matthias Oelze, Michael Hausding, et al.
The Journal of Pharmacology and Experimental Therapeutics|September 11, 2008
Pharmacology of macitentan, an orally active tissue-targeting dual endothelin receptor antagonistMarc Iglarz, Christoph Binkert, Keith Morrison, et al.
Journal of Medicinal Chemistry|August 7, 2012
The discovery of N-[5-(4-bromophenyl)-6-[2-[(5-bromo-2-pyrimidinyl)oxy]ethoxy]-4-pyrimidinyl]-N'-propylsulfamide (Macitentan), an orally active, potent dual endothelin receptor antagonistMartin H Bolli, Christoph Boss, Christoph Binkert, et al.
The Journal of Pharmacology and Experimental Therapeutics|January 10, 2019
Pharmacological Characterization of Aprocitentan, a Dual Endothelin Receptor Antagonist, Alone and in Combination with Blockers of the Renin Angiotensin System, in Two Models of Experimental HypertensionFrederic Trensz, Céline Bortolamiol, Markus Kramberg, et al.
The Journal of Rheumatology|August 16, 2015
The Endothelial-mesenchymal Transition in Systemic Sclerosis Is Induced by Endothelin-1 and Transforming Growth Factor-β and May Be Blocked by Macitentan, a Dual Endothelin-1 Receptor AntagonistPaola Cipriani, Paola Di Benedetto, Piero Ruscitti, et al.
Pageof 5